How Cyclosporine Modifies Histological and Molecular Events in the Vascular Wall During Chronic Rejection of Rat Cardiac Allografts
Overview
Authors
Affiliations
Accelerated allograft arteriosclerosis (chronic rejection) has emerged as a major factor affecting long-term survival of human cardiac allografts. The underlying mechanism of this disorder remains unclear. The purpose of this study was to investigate the effect of cyclosporine on the development of cardiac allograft arteriosclerosis at the cellular and molecular level. Heterotopic rat cardiac allografts from DA donors to WF recipients, with a strong genetic disparity in major histocompatibility complex and non-major histocompatibility complex loci, were used. The allograft recipients received triple-drug immunosuppression consisting of methylprednisolone (0.5 mg/kg/day), azathioprine (2 mg/kg/day), and three different doses of cyclosporine A (CsA; 5, 10, and 20 mg/kg/day). The grafts were removed 3 months after transplantation and processed for histology and immunohistochemistry. Low dose CsA (5 mg/kg/day) was associated with a severe form of intimal cell accumulation and intimal thickening in epicardial arteries and in smaller intramyocardial arterioles with nearly occluded vessel lumens 3 months after transplantation. The intermediate dose CsA (10 mg/kg/day) significantly inhibited arterial intimal thickening but was not efficient in reducing intimal cell accumulation. Instead, high dose CsA (20 mg/kg/day) significantly inhibited all arteriosclerotic vascular wall changes in the allografts. Immunohistochemistry revealed that the occluded epicardial arteries of cardiac allografts with low dose CsA expressed VCAM-1 on the endothelium. Higher CsA doses significantly reduced the expression of endothelial VCAM-1. Neither ICAM-1 nor major histocompatibility complex class II were expressed. Perivascular arterial infiltrates consisting of T helper cells and monocytes/macrophages were a characteristic finding in the allograft with low dose CsA. In the allografts treated with higher doses of CsA, arterial perivascular infiltrates were seldom seen. Our results conclusively demonstrate that sufficient immunosuppression with CsA inhibits intimal thickening and intimal cell accumulation of long-surviving rat cardiac allografts in a dose-dependent fashion. Arteriosclerotic alterations associated with increased expression of arterial endothelial VCAM-1 were totally down-regulated by high doses of CsA.
Animal models for transplant immunology: bridging bench to bedside.
Kang M, Park H, Kim K, Choi D Clin Transplant Res. 2024; 38(4):354-376.
PMID: 39233453 PMC: 11732767. DOI: 10.4285/ctr.24.0029.
Surowka A, Szumilas K, Wilk A, Misiakiewicz-Has K, Ciechanowski K, Kedzierska-Kapuza K Int J Environ Res Public Health. 2022; 19(11).
PMID: 35681984 PMC: 9180580. DOI: 10.3390/ijerph19116399.
An interleukin-6-neutralizing antibody prevents cyclosporine-induced nephrotoxicity in mice.
LaSpina M, Tripathi S, Gatto L, Bruch D, Maier K, Kittur D J Surg Res. 2008; 148(2):121-5.
PMID: 18561950 PMC: 2536771. DOI: 10.1016/j.jss.2007.12.786.
Morphology and immunohistochemistry of rat aortic grafts.
Rossmann P, Lacha J, Lodererova A Folia Microbiol (Praha). 2000; 44(3):339-53.
PMID: 10664891 DOI: 10.1007/BF02818558.
Hachida M, Zhang X, Lu H, Hoshi H, Furutani Y, Matsuoka R Heart Vessels. 1999; 13(1):24-9.
PMID: 9923562 DOI: 10.1007/BF02750640.